Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Fecha de publicación: 01/03/2018

Autores de IIS La Fe

Mariam Aguas Peris

Autor

Participantes ajenos a IIS La Fe

Chaparro, M
Verreth, A
Lobaton, T
Gravito-Soares, E
Julsgaard, M
Savarino, E
Magro, F
Biron, IA
Lopez-Serrano, P
Casanova, MJ
Gompertz, M
Vitor, S
Arroyo, M
Pugliese, D
Zabana, Y
Vicente, R
Shitrit, ABG
Gutierrez, A
Doherty, GA
Fernandez-Salazar, L
Cadilla, JM
Huguet, JM
O'Toole, A
Stasi, E
Marcos, NM
Villoria, A
Karmiris, K
Rahier, JF
Rodriguez, C
Palomares, MDL
Fiorino, G
Benitez, JM
Principi, M
Naftali, T
Taxonera, C
Mantzaris, G
Sebkova, L
Iade, B
Lissner, D
Bradley, IF
Roman, ALS
Marin-Jimenez, I
Merino, O
Sierra, M
Van Domselaar, M
Caprioli, F
Guerra, I
Peixe, P
Piqueras, M
Rodriguez-Lago, I
Ber, Y
van Hoeve, K
Torres, P
Gravito-Soares, M
Rudbeck-Resdal, D
Bartolo, O
Peixoto, A
Martin, G
Armuzzi, A
Garre, A
Donday, MG
de Carpi, FJM
Gisbert, JP

Grupos

Enfermedad Inflamatoria Intestinal

Abstract

OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

Datos de la publicación

ISSN/ISSNe:: 0002-9270, 1572-0241
Tipo:: Article
Páginas:: 396-403
DOI:: 10.1038/ajg.2017.501
PubMed:: 29460920
Factor de Impacto:: 3,668 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

PREGNANCY; INFLIXIMAB; WOMEN; IMMUNOMODULATORS; BIOLOGICS; REGISTRY; THERAPY; AGENTS; PIANO

Campos de Estudio

Cita

Cita Bibliográfica